Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells.

Kailayangiri S, Altvater B, Lesch S, Balbach S, Göttlich C, Kühnemundt J, Mikesch JH, Schelhaas S, Jamitzky S, Meltzer J, Farwick N, Greune L, Fluegge M, Kerl K, Lode HN, Siebert N, Müller I, Walles H, Hartmann W, Rossig C.

Mol Ther. 2019 May 8;27(5):933-946. doi: 10.1016/j.ymthe.2019.02.014. Epub 2019 Feb 23.

PMID:
30879952
2.

Thymidine Metabolism as a Confounding Factor for 3'-Deoxy-3'-18F-Fluorothymidine Uptake After Therapy in a Colorectal Cancer Model.

Schelhaas S, Wachsmuth L, Hermann S, Rieder N, Heller A, Heinzmann K, Honess DJ, Smith DM, Fricke IB, Just N, Doblas S, Sinkus R, Döring C, Schäfers KP, Griffiths JR, Faber C, Schneider R, Aboagye EO, Jacobs AH.

J Nucl Med. 2018 Jul;59(7):1063-1069. doi: 10.2967/jnumed.117.206250. Epub 2018 Feb 23.

3.

Correction to: The relationship between endogenous thymidine concentrations and [18F]FLT uptake in a range of preclinical tumour models.

Heinzmann K, Honess DJ, Lewis DY, Smith DM, Cawthorne C, Keen H, Heskamp S, Schelhaas S, Witney TH, Soloviev D, Williams KJ, Jacobs AH, Aboagye EO, Griffiths JR, Brindle KM.

EJNMMI Res. 2017 Dec 15;7(1):99. doi: 10.1186/s13550-017-0349-1.

4.

3'-Deoxy-3'-[18F]Fluorothymidine Uptake Is Related to Thymidine Phosphorylase Expression in Various Experimental Tumor Models.

Schelhaas S, Heinzmann K, Honess DJ, Smith DM, Keen H, Heskamp S, Witney TH, Besret L, Doblas S, Griffiths JR, Aboagye EO, Jacobs AH.

Mol Imaging Biol. 2018 Apr;20(2):194-199. doi: 10.1007/s11307-017-1125-3.

5.

Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G.

Kailayangiri S, Altvater B, Spurny C, Jamitzky S, Schelhaas S, Jacobs AH, Wiek C, Roellecke K, Hanenberg H, Hartmann W, Wiendl H, Pankratz S, Meltzer J, Farwick N, Greune L, Fluegge M, Rossig C.

Oncoimmunology. 2016 Oct 28;6(1):e1250050. doi: 10.1080/2162402X.2016.1250050. eCollection 2017.

6.

In vivo bioluminescence imaging of neurogenesis - the role of the blood brain barrier in an experimental model of Parkinson's disease.

Fricke IB, Schelhaas S, Zinnhardt B, Viel T, Hermann S, Couillard-Després S, Jacobs AH.

Eur J Neurosci. 2017 Apr;45(7):975-986. doi: 10.1111/ejn.13540. Epub 2017 Mar 7.

PMID:
28194885
7.

Combined PET Imaging of the Inflammatory Tumor Microenvironment Identifies Margins of Unique Radiotracer Uptake.

Zinnhardt B, Pigeon H, Thézé B, Viel T, Wachsmuth L, Fricke IB, Schelhaas S, Honold L, Schwegmann K, Wagner S, Faust A, Faber C, Kuhlmann MT, Hermann S, Schäfers M, Winkeler A, Jacobs AH.

Cancer Res. 2017 Apr 15;77(8):1831-1841. doi: 10.1158/0008-5472.CAN-16-2628. Epub 2017 Jan 30.

8.

Preclinical Applications of 3'-Deoxy-3'-[18F]Fluorothymidine in Oncology - A Systematic Review.

Schelhaas S, Heinzmann K, Bollineni VR, Kramer GM, Liu Y, Waterton JC, Aboagye EO, Shields AF, Soloviev D, Jacobs AH.

Theranostics. 2017 Jan 1;7(1):40-50. doi: 10.7150/thno.16676. eCollection 2017. Review.

9.

Preclinical Evidence That 3'-Deoxy-3'-[18F]Fluorothymidine PET Can Visualize Recovery of Hematopoiesis after Gemcitabine Chemotherapy.

Schelhaas S, Held A, Bäumer N, Viel T, Hermann S, Müller-Tidow C, Jacobs AH.

Cancer Res. 2016 Dec 15;76(24):7089-7095. Epub 2016 Oct 20.

10.

Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3'-Deoxy-3'-[18F]Fluorothymidine in Preclinical Models of Lung Cancer.

Schelhaas S, Held A, Wachsmuth L, Hermann S, Honess DJ, Heinzmann K, Smith DM, Griffiths JR, Faber C, Jacobs AH.

Cancer Res. 2016 Dec 15;76(24):7096-7105. Epub 2016 Oct 26.

11.

The relationship between endogenous thymidine concentrations and [(18)F]FLT uptake in a range of preclinical tumour models.

Heinzmann K, Honess DJ, Lewis DY, Smith DM, Cawthorne C, Keen H, Heskamp S, Schelhaas S, Witney TH, Soloviev D, Williams KJ, Jacobs AH, Aboagye EO, Griffiths JR, Brindle KM.

EJNMMI Res. 2016 Dec;6(1):63. doi: 10.1186/s13550-016-0218-3. Epub 2016 Aug 11. Erratum in: EJNMMI Res. 2017 Dec 15;7(1):99.

12.

PEGylated human serum albumin (HSA) nanoparticles: preparation, characterization and quantification of the PEGylation extent.

Fahrländer E, Schelhaas S, Jacobs AH, Langer K.

Nanotechnology. 2015 Apr 10;26(14):145103. doi: 10.1088/0957-4484/26/14/145103. Epub 2015 Mar 19.

PMID:
25789544
13.

Epigenetic dysregulation of KCa 3.1 channels induces poor prognosis in lung cancer.

Bulk E, Ay AS, Hammadi M, Ouadid-Ahidouch H, Schelhaas S, Hascher A, Rohde C, Thoennissen NH, Wiewrodt R, Schmidt E, Marra A, Hillejan L, Jacobs AH, Klein HU, Dugas M, Berdel WE, Müller-Tidow C, Schwab A.

Int J Cancer. 2015 Sep 15;137(6):1306-17. doi: 10.1002/ijc.29490. Epub 2015 May 29.

14.

Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.

Bäumer S, Bäumer N, Appel N, Terheyden L, Fremerey J, Schelhaas S, Wardelmann E, Buchholz F, Berdel WE, Müller-Tidow C.

Clin Cancer Res. 2015 Mar 15;21(6):1383-94. doi: 10.1158/1078-0432.CCR-13-2017. Epub 2015 Jan 14.

15.

Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-¹⁸F-Fluorothymidine PET and Diffusion-Weighted MR Imaging.

Schelhaas S, Wachsmuth L, Viel T, Honess DJ, Heinzmann K, Smith DM, Hermann S, Wagner S, Kuhlmann MT, Müller-Tidow C, Kopka K, Schober O, Schäfers M, Schneider R, Aboagye EO, Griffiths J, Faber C, Jacobs AH.

J Nucl Med. 2014 Jun;55(6):983-8. doi: 10.2967/jnumed.113.133348. Epub 2014 Apr 28.

16.

Molecular imaging reveals time course of matrix metalloproteinase activity in acute cutaneous vasculitis in vivo.

Steingräber AK, Schelhaas S, Faust A, Jacobs AH, Schäfers M, Goerge T.

Exp Dermatol. 2013 Nov;22(11):730-5. doi: 10.1111/exd.12253.

PMID:
24112050
17.

Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging.

Viel T, Schelhaas S, Wagner S, Wachsmuth L, Schwegmann K, Kuhlmann M, Faber C, Kopka K, Schäfers M, Jacobs AH.

PLoS One. 2013 Jul 4;8(7):e67911. doi: 10.1371/journal.pone.0067911. Print 2013.

18.

Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology.

Viel T, Monfared P, Schelhaas S, Fricke IB, Kuhlmann MT, Fraefel C, Jacobs AH.

Mol Ther. 2013 Mar;21(3):570-9. doi: 10.1038/mt.2012.278. Epub 2013 Jan 15.

Supplemental Content

Loading ...
Support Center